Clinical Trials at Northwestern Medicine Lake Forest Hospital

As of June 2026, 58 paid clinical trials are recruiting at Northwestern Medicine Lake Forest Hospital, located at 1000 N WESTMORELAND RD, LAKE FOREST, IL 60045-1658, phone (847) 234-5600 in Lake Forest, Illinois. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

58 clinical trials at Northwestern Medicine Lake Forest Hospital

·Clear filters·↓ Download CSV

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

1021 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting

Apply to this trial

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

for Advanced Extrapulmonary Neuroendocrine Carcinoma

Drug: Atezolizumab

249 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05058651·Phase 2, Phase 3·Recruiting

Apply to this trial

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

for Metastatic Malignant Neoplasm in the Liver

446 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT05040360·Phase 2·Recruiting

Apply to this trial

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

for Stage I Breast Cancer

812 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: All·Age: 50 - 70

Code: NCT04852887·Phase 3·Recruiting

Apply to this trial

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

for Recurrent Head and Neck Squamous Cell Carcinoma

178 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 79

Code: NCT04671667·Phase 2·Recruiting

Apply to this trial

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

for Metastatic Clear Cell Renal Cell Carcinoma

387 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04510597·Phase 3·Recruiting

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

621 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting

Apply to this trial

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

for Recurrent T Acute Lymphoblastic Leukemia

163 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 12+

Code: NCT04315324·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

for Acral Lentiginous Melanoma

Drug: Ipilimumab

331 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04511013·Phase 2·Recruiting

Apply to this trial

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

for Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Drug: Bevacizumab

604 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04181060·Phase 3·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

for Pancreatic Neoplasm

408 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 50 - 75

Code: NCT04239573·Recruiting

Apply to this trial

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

for Metastatic Small Intestinal Adenocarcinoma

536 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT04205968·Phase 2·Recruiting

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

Drug: Cabozantinib

578 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

275 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03739814·Phase 2·Recruiting

Apply to this trial

Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer

for Previously Treated Non-Small Cell Lung Cancer

1229 locations incl. Birmingham

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03851445·Phase 2, Phase 3·Recruiting

Apply to this trial

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

for Breast Cancer

451 locations incl. Fairbanks

Sponsor: Canadian Cancer Trials Group

Sex: Female·Age: 35+

Code: NCT03488693·Phase 3·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia

455 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18 - 39

Code: NCT03150693·Phase 3·Recruiting

Apply to this trial